1. In Vivo
  2. >>Deal-Making

Big Pharma Licensing Growth Slows In 2016

 
• By Amanda Micklus

Big pharma licensing deal volume grew 12% between 2012 and 2016, but according to a new report from Datamonitor Healthcare there were fewer deals and dollars attributed to partnerships in 2016.

IV1703_WordCloud_BigPharma_1200

Big pharma licensing deal volume grew by 12% over the last five years, but 2016 proved to be a difficult year with fewer deals and dollars attributed to partnerships, likely due to regulatory and political pressures. The pursuit of innovative cancer products to advance the standard of care continue to make oncology the leading area in alliances overall, and among the top five deal-makers AstraZeneca PLC, Johnson & Johnson, Roche, Pfizer Inc., and Merck & Co. Inc.

Between 2012 and 2016, Datamonitor Healthcare's big pharma peer set – 16 companies with revenues exceeding $10 billion – signed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.